Immunome Inc. (IMNM)
NASDAQ · Healthcare
Immunome Inc. EBITDA 2023–2025
Immunome Inc. annual/quarterly ebitda history and growth rate from 2023 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Immunome Inc. ebitda for the quarter ending March 31, 2026 was -58.7 M, a 33.40% increase year-over-year.
- Immunome Inc. ebitda for the twelve months ending March 31, 2026 was -239.3 M.
- Immunome Inc. annual ebitda for 2025 was -221.6 M, a 27.15% decrease from 2024.
- Immunome Inc. annual ebitda for 2024 was -304.2 M, a 178.93% increase from 2023.
- Immunome Inc. annual ebitda for 2023 was -109.1 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Immunome Inc. EBITDA — FAQ
Immunome Inc. (IMNM) ebitda over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IMNM's ebitda history?
The chart and table above show Immunome Inc.'s ebitda by year and by quarter, including the growth rate.